家族性自主神经失调综合征（Familial dysautonomia syndrome, FD）是一种少见的家族性常染色体隐性遗传病，主要以神经功能障碍、特别是自主神经失调为特征的一组临床症状。该病又称Riley-Day综合征、家族性自主神经功能不全症、中枢性自主神经不全综合征等。 

超过9%的FD个体的纯合突变为ELP1基因的20内含子发生IVS20+6T>C突变，这种突变破坏了U1小核核糖核蛋白与内含子20供体剪接位点的碱基配对，导致外显子20编码序列的跳跃。该转录本的错误剪接在转录本中引入了移码，并且该mRNA的翻译产生截短的79kDa蛋白质^[1-2]。 

使用小鼠模型研究改变人类细胞剪接过程是充满挑战的，因为两者剪接过程不同^[3]，对于该内含子点突变导致的疾病研究更是如此。已有文献表明，纯合敲除该基因会导致胚胎致死；而直接在野生型小鼠中表达带有人源突变的基因，可能由于表达了正常水平的内源性小鼠ELP1，故没有明显疾病表型^[4-6]。为此，赛业生物自主研发了ELP1全基因组人源化小鼠，及在此基础上构建的热门点突变人源化疾病模型。 

不仅是上述提及的疾病，针对视网膜色素变性（RP）、黄斑变性（AMD）、帕金森病（PD）等多种疾病类型，如果要深入研究其致病机理，长片段甚至全基因组人源化小鼠是更好的选择。但全基因组替换所需的技术难度高，大规模引入的外源序列可能会影响原本基因的表达调控。 

为此，赛业生物启动了HUGO-GT^TM计划，基于自主研发的TurboKnockout-Pro技术，对鼠源基因实现原位替换，成功构建了涵盖更丰富干预靶点的全基因组人源化小鼠。HUGO-GT^TM小鼠搭载了更高效的大片段载体融合技术，可以作为万能模板进行针对性的突变定制服务，是更贴近真实世界生物机制的药物临床前研究模型。 

注：HUGO-GT^TM即Humanized Genomic Ortholog for Gene Therapy 

精选模型推荐

更多推荐

[1]Carmel I , Tal S , Vig I ,et al.Comparative analysis detects dependencies among the 5′ splice-site positions[J].RNA, 2004, 10(5):828-840.DOI:10.1261/rna.5196404.

[2]Anderson S L , Coli R , Daly I W ,et al.Familial Dysautonomia Is Caused by Mutations of the IKAP Gene[J].The American Journal of Human Genetics, 2001, 68(3):753-758.DOI:10.1086/318808.

[3]Pan Q , Bakowski M A , Morris Q ,et al.Alternative splicing of conserved exons is frequently species-specific in human and mouse.[J].Trends in Genetics, 2005, 21(2):73-77.DOI:10.1016/j.tig.2004.12.004.

[4]Hims M M , Shetty R S , Pickel J ,et al.A humanized IKBKAP transgenic mouse models a tissue-specific human splicing defect.[J].Genomics, 2007, 90(3):389-396.DOI:10.1016/j.ygeno.2007.05.012.

[5]Chen Y T , Hims M M , Shetty R S ,et al.Loss of Mouse Ikbkap, a Subunit of Elongator, Leads to Transcriptional Deficits and Embryonic Lethality That Can Be Rescued by Human IKBKAP[J].Molecular and Cellular Biology, 2009, 29(3):736-744.DOI:10.1128/MCB.01313-08.

[6]Dietrich P , Yue J , Shuyu E ,et al.Deletion of Exon 20 of the Familial Dysautonomia Gene Ikbkap in Mice Causes Developmental Delay, Cardiovascular Defects, and Early Embryonic Lethality[J].Plos One, 2011, 6(10):e27015.DOI:10.1371/journal.pone.0027015.

[7]Ansseau Eugénie,Vanderplanck Céline, Armelle W ,et al.Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)[J].Genes, 2017, 8(3):93.DOI:10.3390/genes8030093.

[8]Lim K R Q , Maruyama R , Echigoya Y ,et al.Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy (vol 117, pg 16509, 2020)[J].Proceedings of the National Academy of Sciences of the United States of America.  2020(35):117.

[9]Ba L M W , Garwick S E , Mei W ,et al.DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo.[J].Annals of Neurology, 2011, 69(3):540-552.DOI:10.1002/ana.22275.

[10]Yin Q , Wang H , Li N ,et al.Dosage effect of multiple genes accounts for multisystem disorder of myotonic dystrophy type 1[J].Cell Research, 2019, 30(2):1-13.DOI:10.1038/s41422-019-0264-2.

[11]Mahadevan M S , Yadava R S , Yu Q ,et al.Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.[J].Nature Genetics, 2006, 38(9):1066.DOI:10.1038/ng1857.

[12]Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, Krym M, Thornton CA. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 2000 Sep 8;289(5485):1769-73. doi: 10.1126/science.289.5485.1769. PMID: 10976074.